



KINEXUS

Kinexus Bioinformatics Corporation Announces the Appointment of Two New Directors to its Board

Senior Executives Bring Substantial Expertise and Leadership to the Kinexus Board

FOR IMMEDIATE RELEASE August 4, 2005

VANCOUVER, British Columbia - Kinexus Bioinformatics Corporation, is pleased to announce the election of Mr. Don Enns and Mr. Ross MacLachlan to the Company's Board of Directors at its recent Annual General Meeting. "We are extremely pleased to welcome these two high-caliber executives to our Board," said Dr. Steven Pelech, Founder, Director, President and Chief Scientific Officer of Kinexus. "Their substantial experience and leadership in the healthcare and high technology industries coupled with strong corporate and business development backgrounds will be an asset as Kinexus continues to pursue its strategic objective of becoming a world leader in the proteomics and bioinformatics world markets.

Mr. Don Enns has been actively involved in the Canadian life sciences and health care industry for over 20 years. He is currently the President of Cantest, a full service laboratory providing professional analysis and consultation in environmental, biotechnology, pharmaceutical, food safety and industrial hygiene related fields. Mr. Enns sits on the boards of several local companies involved in the life sciences field and has held the presidency of several non-profit organizations involved with national standardization and public health. Mr. Enns has been instrumental in Cantest's expansion into the European and Southeast Asian markets, and his experience overseas includes laboratory consulting, business development and mergers and acquisitions.

Mr. Ross MacLachlan is an experienced business executive and entrepreneur with a successful track record as a founder and investor in several innovative and early stage technology companies. He is regularly engaged as a management consultant, specializing in the development of strategic planning and early stage execution. Until recently, he worked with Haywood Securities in a corporate finance role as Entrepreneur in Residence and now serves in an executive capacity or on the board of several of their recent investments, which include Rimon Therapeutics, a medical polymers company, Lignol Innovations, an industrial biotech company utilizing ethanol technology, Response Biomedical an immunoassay medical device company, and Pristine Power an independent electrical power producer.

Kinexus Bioinformatics Corporation is a private, biotechnology company engaged in the development of innovative methods to establish the relationships of signalling proteins within cellular communication networks. The application of this knowledge strategically positions Kinexus and its clients to advance disease diagnosis, drug discovery and development and personalized therapies to improve human health.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.

PRESS RELEASE - 2005 AUGUST 4